Feasibility and safety of physical exercise in men with prostate cancer receiving androgen deprivation therapy and radiotherapy: a study protocol.
accidental falls
androgen deprivation therapy
bone fractures
exercise
prostatic neoplasms
radiotherapy
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
entrez:
16
3
2022
pubmed:
17
3
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) and radiotherapy (RT) increase survival in selected patients with prostate cancer. Nevertheless, the side effects of these therapies are associated with an increased risk of accidental falls and fractures and a decreased quality of life. Preliminary evidence suggests that physical exercise can be a valid strategy to reduce the side effects of ADT and RT in men with prostate cancer. Despite this knowledge, most patients with prostate cancer are insufficiently active, and there is a lack of data on the safety and adherence to the recommended dose of physical exercise. This study protocol is designed to examine the feasibility and safety of a multicomponent experimental physical exercise intervention targeting psychophysical and cognitive functions and the quality of life in this population. This is a pilot feasibility study. Twenty-five men currently treated with ADT and RT for prostate cancer will be invited to participate in a 20-week, multicomponent physical exercise intervention, including supervised and unsupervised exercise sessions and meeting the current recommendation for exercise in cancer. The primary outcomes are physical exercise feasibility (recruitment, adherence and drop-out rates) and safety (adverse events related and unrelated to the intervention). The secondary outcomes are muscle strength, balance, fatigue, symptoms of anxiety and depression, cognitive function, quality of life, and patient satisfaction. We will also record the number of accidental falls and fractures occurring during the intervention and at 1 year of follow-up. The study has received ethics approval from The Area Vasta Nord Local Ethics Committee (Province of Reggio Emilia, 23 June 2020, Number 520/2020/SPER/IRCCSRE). Recruitment began in September 2020 and will be completed in September 2021. The results will be disseminated through scientific journals and conference presentations. NCT04500080.
Identifiants
pubmed: 35292485
pii: bmjopen-2021-048854
doi: 10.1136/bmjopen-2021-048854
pmc: PMC8928322
doi:
Substances chimiques
Androgen Antagonists
0
Androgens
0
Banques de données
ClinicalTrials.gov
['NCT04500080']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e048854Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Rehabil Med. 2016 Jul 18;48(7):597-603
pubmed: 27344968
Support Care Cancer. 2022 Feb 22;:
pubmed: 35194723
Med Sci Sports Exerc. 2009 Mar;41(3):687-708
pubmed: 19204579
Urology. 2006 Jan;67(1):125-30
pubmed: 16413347
Sports Med Open. 2020 Jul 17;6(1):31
pubmed: 32681399
Front Oncol. 2019 Sep 26;9:918
pubmed: 31616633
Oncology. 2018;94(6):363-372
pubmed: 29514170
Support Care Cancer. 2020 Aug;28(8):3921-3926
pubmed: 31858249
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Physiother Theory Pract. 2012 Nov;28(8):571-87
pubmed: 22315947
Eur Urol. 2016 Apr;69(4):693-703
pubmed: 26632144
Eur J Cancer Care (Engl). 2019 Sep;28(5):e13076
pubmed: 31050091
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390
pubmed: 31626055
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Phys Ther. 2022 Mar 1;102(3):
pubmed: 34972863
Int J Sports Med. 2013 Jul;34(7):631-6
pubmed: 23444095
Int J Behav Nutr Phys Act. 2020 Nov 26;17(1):150
pubmed: 33239014
Phys Ther. 2019 Sep 1;99(9):1242-1254
pubmed: 31189180
Cochrane Database Syst Rev. 2018 Sep 19;9:CD010192
pubmed: 30229557
CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49
pubmed: 24916760
J Cancer Educ. 2020 Oct;35(5):946-953
pubmed: 31119707
J Urol. 2005 Sep;174(3):1065-9; discussion 1069-70
pubmed: 16094059
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
J Pain Symptom Manage. 2001 Dec;22(6):1007-15
pubmed: 11738163
Med Sci Sports Exerc. 2011 Jul;43(7):1334-59
pubmed: 21694556
Curr Oncol. 2015 Dec;22(6):374-84
pubmed: 26715869
Med Sci Sports Exerc. 2004 Nov;36(11):1985-96
pubmed: 15514517
J Strength Cond Res. 2018 May;32(5):1360-1365
pubmed: 28557849
Eur J Appl Physiol. 2013 Jan;113(1):147-55
pubmed: 22615009
J Natl Compr Canc Netw. 2019 May 1;17(5.5):583-586
pubmed: 31117038
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Eur J Cancer Care (Engl). 2020 Jan;29(1):e13193
pubmed: 31797478
Psychooncology. 2018 Oct;27(10):2339-2348
pubmed: 30255558
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Psychooncology. 2019 Dec;28(12):2270-2285
pubmed: 31617635
BMJ Support Palliat Care. 2020 Aug 13;:
pubmed: 32792420
Med Sci Sports Exerc. 2019 Nov;51(11):2391-2402
pubmed: 31626056
J Am Geriatr Soc. 1986 Feb;34(2):119-26
pubmed: 3944402
Br J Cancer. 1998 Oct;78(7):907-12
pubmed: 9764582
Support Care Cancer. 2021 Apr;29(4):1811-1824
pubmed: 33119791
Phys Ther. 2006 Jul;86(7):944-54
pubmed: 16813475
PLoS One. 2017 Aug 14;12(8):e0182554
pubmed: 28806753
Support Care Cancer. 2020 May;28(5):2079-2093
pubmed: 31912360